Sage Therapeutics have today announced that they have ceased development of a drug designed to target cognitive impairment in Huntington’s Disease. Unfortunately, the drug did not meet what it needed to demonstrate its effectiveness.

You can read the announcement from Sage Therapeutics below. The company have said they will provide further updates, and we will let you know of any other information when we have it.  

You can also read the HD Buzz article about the announcement.

Sharing Difficult News – Sage Therapeutics Announces Topline Results of the Phase 2 DIMENSION Study of Dalzenemdor (SAGE-718)
 
Today, Sage Therapeutics announced the results of the Phase 2 DIMENSION Study of the investigational oral medicine dalzanemdor (SAGE-718) in people with cognitive impairment associated with Huntington’s Disease (HD).
 
The DIMENSION study did not demonstrate a statistically significant difference in participants treated with dalzanemdor versus placebo on the primary endpoint, which was the Symbol Digit Modalities Test (SDMT), an assessment used by researchers and clinicians in evaluating cognitive impairment in HD. Additionally, none of the secondary endpoints demonstrated statistically significant or clinically meaningful differences.
 
Based on these data, Sage has made the difficult decision to cease development of dalzanemdor in HD or other indications, including closing the ongoing PURVIEW open-label rollover safety study in patients with HD. For further information, please see the press release.


Sage Therapeutics said,
 
“With no approved medicines targeting cognitive impairment in Huntington's disease, we know you feel a profound sense of loss with this news.  We are here with you in sadness and disappointment.  Our deepest gratitude goes to everyone who contributed to this critically important work, including study participants, family members, care partners and advocates. Our admiration for this remarkable advocacy community is boundless and we join you in hope for a treatment option so desperately needed.”
 
Cath Stanley, Chief Executive Officer of the Huntington’s Disease Association, said,

We are sorry to share this news today and thank Sage Therapeutics for their honesty in sharing this information. We will continue to support companies trying to find an effective treatment for Huntington’s disease.

Healthcare professionals can request more information through a medical inquiry request form